Objective:

Precure, LLC aims to identify biological changes that occur before disease symptoms emerge by linking molecular data with longitudinal clinical information.

Approach:

• Data generation: The initiative plans to generate proteomic and genomic data from one million biospecimens and connect these data with clinical information collected over several years.
• Analysis: Artificial intelligence and large-scale data analytics will be used to identify patterns and potential biological insights.
• Partnership: Mayo Clinic will hold a majority stake; Thermo Fisher Scientific will be a founding partner and minority owner, contributing proteomics expertise and technologies, including Olink Explore HT and Thermo Scientific Orbitrap Mass Spectrometry.

Key Findings:

• Precure is a newly launched company formed by Mayo Clinic and Thermo Fisher Scientific.
• The planned dataset is intended to support research across cancer, cardiometabolic disease, neurological disorders, and immune-mediated conditions.
• The company will complement Mayo Clinic’s investigator-led Precure Research program by providing infrastructure, scale, and external collaborations.
• Mayo Clinic says financial returns from the venture will be reinvested in its patient care, research, and education missions.

Interpretation:

The initiative is designed to build population-level molecular datasets to study disease development before symptoms appear and support development of diagnostics, therapeutics, and other healthcare technologies.

Limitations:

• The context describes plans and intended uses; it does not report completed data generation or research outcomes.
• No study methods, participant characteristics, or performance results are provided.

Sources:

• Mayo Clinic